Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't think the open interest (as far as I can remember) was big on that strike price. So, the volume must be opening position. It could slightly off if some positions are being sold into the volume. We would know what the numbers are tomorrow or on Monday when they update the open interest.
Also, the bid and ask has gone up by 5 cents which could mean it is a purchase.
-vg_future
High volume (over 3K) on May 19th $9.50 strike price calls. Some pretty heavy betting going on.
-vg_future
Nice updates on the ST regarding the presentation including ALS potentially being the undisclosed target.
I still believe that there will be another update from Anavex this week.
JMHO,
vg_future
It is possible that there could be some unpublished data/analysis in there…so, we might have to wait until Monday…hopefully for a PR release. Just my WAG (Wild A$$ Guess).
It is also possible that the unpublished data is what Anavex announced on Thursday last week. Still my WAG.
Isn’t he still in Australia or maybe he is just back. So, he can do a PR and call following it here in US (maybe some updates from Australia as well). He doesn’t have to (or maybe cannot) go to this conference.
-vg_future
That is possible and is typical of hiring announcements/statements. But, Anavex announcing it now (vs when it actually occurred), could it be that the company is setting the stage for the authenticity and validation of the data (so that Wall Street can see it) before it is announced?
TIA,
vg_future
Coudn't agree more. Any insights on why it is listed as "Late Breaking Oral...." (as mentioned by or that is a typical way how oral presentations are qualified at CTAD? I think that means a lot and shows confidence in results.
-vg_future
Yes, got it (I just realized that today's closing price is less than the award price of 10.09 ).
I was referring to the amount of around 500K which seemed big and most likely tied with something key/significant (IMO) milestone. Hoping for some good NEWS.
-vg_future
The option grants (50K @ 10.09) seem pretty big, so I would say they are tied with some event (not sure which one...could be completion of AD or PDD OLE data ready or submission to FDA...just guesses). I am expecting to see one more big one that goes to Dr.Missling.
Hoping for NEWS soon.
-vg_future
Exactly. These patients definitely need a break and Anavex is giving it to them....through their medicine and proven results (personally verified by the patients themselves) and some additional hope (never hurts to see the brighter prospects).
-vg_future
Great post tradeherpete! Couldn't agree more or said it any other way. Excellent!
-vg_future
Bourbon...if I may interject....I understand that we are/were all hoping for better NEWS/results by now, but there is progress if you look at it. The update Meeting with FDA for discussing is encouraging...it is not "Planned to meet" anymore. I guess things are moving along now....into actions.
Also, the cash position of $153.3 million is encouraging...looks like we have ended up with more money than last quarter in spite of spending over $10 million this quarter.
Bright/interesting tidbits from this morning's PR
From PR:
- Meeting with FDA for discussing ANAVEX®2-73 Parkinson’s disease program including pivotal Phase 3 study.
(please note the "Meeting" word as opposed to "Planned to meet"...so, this is actively happening now...hopefully more color will be provided during the CC this evening.
- Cash and cash equivalents of $153.3 million on March 31, 2022
(cash and cash equivalents were at 151.1 million at the end of Dec, 2021....so that is an increase of 2.2 million in spite of burn rate of 10.9 million roughly...effectively making it a 13.1 million increase in cash...revenue, grant or otherwise)
There are other highlights as well, but these 2 caught my eye.
Good luck to the long shareholders.
-vg_future
end2war, good explanation. Makes sense.
OT - SAVA related Citizen's petition rejected by FDA on kind of technicality..I think petition didn't present any facts, but has instead requested FDA do the fact finding for the allegations. FDA cannot investigate what the petition is requesting and hence denied the request. SEC investigation on SAVA is still on though.
Our AVXL has a clean chit and hope the market recognizes that fact and gives due respect.
-vg_future
RedShoulder, yes, I agree. There are some really nice posts over there. Good to hear about the background on "Mighty Kurtz". The info that he afforded is very valuable and encouraging.
-vg_future
From stocktwits...poster and the post seemed to be genuine...no way for me to check/confirm though. But, FWIW (I underlined part where he quoted correspondence/communication with IR)
Veliger
I fully expect we see a lot more behind the curtain tomorrow. More transparency with what is going on with PDD (per IR this morning), and where the numerous, other trial starts are (i.e. Fragile X, ultra rare diseases). At a minimum there will be definitive answers for RETT filing strategy and when. Any dialogue or Q&A around partnership would also be welcome. I’d love to see this serve as catalyst for some upgrades, following avatar data and strategy.
The points seem to be touching the most common questions on the board. Thanks to "Veliger" for the post.
-vg_future
Thanks a bunch RedShoulder. Much appreciated.
As we see here...the answer is clear, but unfortunately, the lapse in putting a complete statement together and assuming that it will be understood gave the A##F an opening to spew his junk. Great missed opportunity for the company. However, I liked the part where the IR guy said "There will be a clear and concrete plan laid out for the company". I am itching to go out on a limb and say, probably what they are going to share next week from plans perspective will make this week a non-issue and hence there might be slight attitude from the company's perspective that A##F would be taken care of while long term shareholders and the "CNS patient" community are being rewarded.
-vg_future
Thanks RedShoulder. Please post the second part of the conversation...with more meat. I don't want to steal the flow from you....I really liked part of the last bit in there.."concrete plan laid out for the company"
-vg_future
Thanks to Missling for putting out the clarification...it answered my earlier question (directly/indirectly) about the change in phase 2 to 3 and change of the end point...
from the IBD article.
https://finance.yahoo.com/m/e06e7d2d-237e-359d-954b-618beecb551f/anavex-ceo-says-inaccurate.html
"The company also decided then to upgrade the study to a Phase 3 test based on confidence in earlier studies, Missling said. The new measures selected offer a better look at the drug's benefit, he said."
Straight from the horses mouth.
-vg_future
Okay, got it.
-vg_future
powerwalker, thanks for the details. I remember seeing something, but didn't have details.
Thanks,
vg_future
Question to anyone...is it possible that Anavex met the original end points as a part of phase 2 and also the new end points as a part of phase 3....meaning we not only good for the original trial and also we proved the next phase as well trough the same trials (2b/3 designation might have been designed liked that)? All this unraveled during the analysis of the data...maybe as per design (2b/3).
I think that is what Missling saying..we met even tougher standards than the original ones.
-vg_future
thanks for the link and your article Mayo.
Chrisp5, good catch and point. Maybe that is an opportunity for Anavex to clarify (explain and show how the new end point is more relevant and maybe more superior....most importantly...FDA asked for this since that it is the right thing to track and since FDA asked..the approval might be more easier once we meet) this mess officially in a PR.
-vg_future
yep, couldn't agree more.
AF tweets are not just debatable...they are criminal. I think there was an investigation or case against him regarding these manipulations. Luckily, for him, a significant portion of the biotech stocks turn out to be duds (either intentionally by manipulative design to ride the wave or by unforeseen hurdles during and after trials...and of course by results). So, he can hide behind his manipulation traits making accusations and wild a## guesses to fit his agenda and still turn out right/correct just because of the nature and reality of the biotech field. But, in this case, he should be taken to the mat so that he can squeal. Anyway, I digress.
I think Missling made it clear during the conference call about the change and I think he is excited enough about the results. So, I wouldn't suspect anything there. But, maybe he could have pre-empted this attack by announcing any changes in the end points with the proper instructions or guidance from FDA. Again, I might be playing an armchair CEO here and my opinion should be viewed in that context. For now, I am just hating the fact that a great opportunity to get a big jump on great phase 3 results is lost...at least temporarily for today. Tomorrow is a whole another day.
-vg_future
Looks like a hit piece...the article had incomplete and incorrect statements to fit the headlines. The problem with these headlines is that they cause the damage and when they issue a correction...no one sees them. Very sneaky way of stock manipulation.
From Anavex's perspective...could they have issues a PR two weeks back clarifying the situation....along the lines of..."FDA wanted more rigorous and accurate end point" or "It is done as per the original FDA approved plan to make the study....". That would have helped by preparing the ground.
Anyway, we shall bounce form this too.
-vg_future
falconer66a, yes, I like how the experts in the field are slowly speaking up..there was a message/post saying that European RETT organization has said that the results are great. They definitely know more than this crook. I understand that revenues will speak for themselves (with numbers there is no slanted interpretation), but, in biotech the phase 3 results (in fact, sometimes even phase 2) will also speak loudly...and this culprit and his cabal are trying to steal the magic effect of great phase 3 results. I just wish someone rubs his nose in the stink that he spreads (JMH hope).
-vg_future
Well said. Having a discussion with AF is worthless...that should be left to the shorts who will be ripped and stripped soon with his guidance. I wish some independent scientific article and maybe even the RETT association comes out with the right assessment of the results and state how excited they are.
-vg_future
end2war, it is intentional misleading by few...not mis-understanding. These crooks are specifically led/fed by AF. I hope someone takes criminal action against this guy.
-vg_future
Thanks tradeherpete.
-vg_future
Thanks Mayo.
That is true too....either by hidden agenda or driven by sincerity, they might be the whistleblowers.
I am glad that AVXL is being open and clear on the data...no pumping or manipulation.
-vg_future
Yes, can't imagine all the analysts and wallstreet firms that were pumping them up with hands in the jar (conflict of interest?). Folks might choose soft words like oversight, maybe mistake, or what not....there is no OOPS in this business...particularly when so much of money (greed) is involved at the expense desperately waiting patients.
I believe and seriously hope for AVXl fix this non-sense once for all and help the patients. Waiting patiently...
-vg-future
Yep. Hope he does. It can be viewed as AVXL being genuine.
-vg_future
If SAVA noise/complaint is true and justified, it would explain why SAVA is trying to sell itself before even trying to proves its drug. It looks like a classic "street + company" duo playing with unsuspecting investors and speculators.
This should help AVXL because it is definitely clean and doing the things the right way
- leaving no room for data manipulation and
- letting the results speak for themselves
- proving the drug at every step.
-vg_future
Thanks MayoMobile. Much appreciated.
Thanks for the post raja48185. This shows lot of things about the whole SAVA stuff
- how analysts pumped it
- how SAVA re-worked the data after initial failure announcement (like Biogen)
- how SAVA is desperate to sell itself to someone else
I wish Anavex gets its real recognition soon and not get caught in the SAVA and Annovis non-sense/noise/manipulation.
-vg_future
RedShoulder, good one. Anavex did find a worthy investor rather than the typical investment firms. Maybe this leads to a partnership with other big firms or bio companies out there.
-vg_future